Effect of stone composition on surgical stone recurrence: single center longitudinal analysis.

INTRODUCTION The objective of this study is to explore the association between urinary stone composition and surgical recurrence. MATERIALS AND METHODS: Patients who underwent kidney stone surgeries (between 2009-2017), were followed for > 1 year, and had ≥ 1 stone composition analyses were included in our analysis. Surgical stone recurrence (repeat surgery) was defined as the second surgery on the same kidney unit. Recurrence-free survival analysis was used. RESULTS: A total number of 1051 patients were included (52.7% men, average age 59.1 +/- 15.1 years). Over 4.7 +/- 2.5 years follow up, 26.7% of patients required repeat surgery. Patients' stone compositions were calcium oxalate (66.0%), uric acid (12.2%), struvite (10.0%), brushite (5.7%), apatite (5.1%) and cystine (1.0%). Results suggested that patients with cystine stones had the highest surgical recurrence risk; brushite had the second-highest surgical recurrence risk. Struvite, uric acid, and apatite stones were at higher risk compared with calcium oxalate stones (lowest risk in our cohort). When pre and postoperative stone size was controlled, patients with a history of uric acid, brushite, and cystine stones were at higher surgical risk. After controlling clinical and demographic factors, only brushite and cystine stones were associated with higher surgical recurrence. CONCLUSIONS: Patients with cystine stones had the highest surgical recurrence risk; brushite stones had the second highest surgical recurrence risk. Struvite, uric acid, and apatite stones were at higher risk compared with calcium oxalate stones. When pre and postoperative stone size, clinical and demographic factors were controlled, only those with brushite or cystine stones were at significantly higher risk of surgical recurrence.

Role of Residual Fragments on the Risk of Repeat Surgery after Flexible Ureteroscopy and Laser Lithotripsy: Single Center Study.

PURPOSE: We analyzed the impact of residual stone fragments seen on abdominal x-ray after ureteroscopy and laser lithotripsy on the risk of repeat surgical intervention. MATERIALS AND METHODS: Our study included 781 patients (802 renal units) who underwent ureteroscopy and laser lithotripsy with abdominal x-ray within 3 months postoperatively and who had at least 1 year of followup. Ureteroscopy and laser lithotripsy were performed using the dusting technique. We analyzed the association between surgical recurrence-free survival and the size of the largest residual fragment. RESULTS: During a median followup of 4.2 years repeat surgery was performed on 161 renal units (20%). Of the repeat interventions 75% were done for symptomatic nephrolithiasis. Postoperative imaging showed residual stone fragments in 42% of cases. In the entire group the risk of repeat surgery was increased in renal units with residual fragments greater than 2 mm. The effect of the size of residual fragments on the risk of surgical recurrence varied by patient body mass index. It was much larger in nonobese subjects, who were at increased risk for repeat surgery with residual fragments of any size. In the obese subgroup only fragments greater than 2 mm increased the risk of surgical recurrence. CONCLUSIONS: The association between the size of residual stone fragments detected by abdominal x-ray after ureteroscopy and laser lithotripsy, and the risk of repeat surgical intervention depends on patient body mass index. Nonobese patients with residual stone fragments of any size are at increased risk for repeat intervention compared to those with a negative abdominal x-ray. The predictive value of abdominal x-ray after ureteroscopy and laser lithotripsy is limited in obese patients.

Clinical and demographic predictors of repeat stone surgery.

OBJECTIVE: To identify the clinical and demographic predictors of repeat stone surgery. MATERIALS AND METHODS: We retrospectively analysed 1496 consecutive patients, aged > 18 years, who underwent stone surgery at our institution in the period from January 2009 to May 2017 and who had at least 12 months of postoperative follow-up. We defined surgical recurrence as repeat surgery on the same renal unit or on the opposite renal unit if the original imaging did not demonstrate significant stones on that side. Characteristics associated with the risk of surgical recurrence in univariate Cox regression analysis were entered into a multivariate model. RESULTS: Most patients underwent ureteroscopy and laser lithotripsy (83.0%). Approximately 60% of the patients had a personal history of stone disease and 50% were obese. Over a mean (median; interquartile range) follow-up of 4.1  (3.9; 2.4-5.9) years, 24.5% of patients had surgical recurrence, with 82% of repeat surgeries performed for symptomatic nephrolithiasis. The factors associated with increased risk of surgical recurrence in the multivariate model were: age <60 years, female gender, malabsorptive gastrointestinal disease, diabetes, recurrent urinary tract infections, personal history of nephrolithiasis, renal stones and bilateral nephrolithiasis. The hazard ratios for these variables ranged within an interval of <0.5 (from 1.30 to 1.71). CONCLUSION: We identified eight demographic and clinical factors associated with increased risk of repeat renal stone surgery. These factors could be combined as a numerical count that allows stratification of patients into low-, intermediate- and high-risk subgroups.

Clinical Impact of the Institution of Moses Technology on Efficiency During Retrograde Ureteroscopy for Stone Disease: Single-Center Experience.

Objective: To evaluate the clinical benefits of Moses technology compared with the regular mode with the Lumenis® Pulse™ P120H holmium laser during ureteroscopy for stone disease. Patients and Methods: An IRB-approved database of patients with urolithiasis was analyzed for ureteroscopies from January 2020 to December 2020 at an outpatient surgery center. Patients who underwent ureteroscopy with the Lumenis Pulse P120H holmium laser system with the Moses or regular mode were included. Patient characteristics and stone parameters were collected. Operative room parameters were compared, including procedural time, fragmentation/dusting time, lasing time, and total energy used. Complication rates and stone-free rates were also analyzed. Univariate analysis and multiple analysis of covariance controlling for cumulative stone size were performed. Patients with staged procedures were excluded. Results: Of 197 surgical cases, 176 met the inclusion criteria. Moses was utilized in 110 cases and regular mode in 66. There was no difference in cumulative stone size between Moses and regular modes (11.8 ± 7.9 vs 11.6 ± 9.2 mm, p = 0.901). Procedural time (43.5 ± 32.1 vs 39.8 ± 24.6 minutes, p = 0.436), fragmentation/dusting time (20.5 ± 25.3 vs 17.1 ± 16.1 minutes, p = 0.430), lasing time (7.5 ± 11.1 vs 6.7 ± 7.9 minutes, p = 0.570), and total energy used (5.1 ± 6.7 vs 3.8 ± 4.8 kJ, p = 0.093) were also similar. Complications (6.4% vs 6.1%, p = 0.936) and stone-free rates (52.3% vs 65.3%, p = 0.143) did not differ. Conclusion: At our institution, Moses technology did not significantly change the procedural time, fragmentation/dusting time, lasing time, or total energy used. Moreover, there were no differences in complications or stone-free rates. There may be technical benefits to the Moses technology not captured in this analysis.

Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence.

BACKGROUND: Postprostatectomy adjuvant or salvage radiotherapy, when using standard fractionation, requires 6.5 to 8 weeks of treatment. The authors report on the safety and efficacy of an expedited radiotherapy course for salvage prostate radiotherapy. METHODS: A total of 108 consecutive patients were treated with salvage radiation therapy to 65 grays (Gy) in 26 fractions of 2.5 Gy. Median follow-up was 32.4 months. Median presalvage prostate-specific antigen (PSA) was 0.44 (range, 0.05-9.50). Eighteen (17%) patients received androgen deprivation after surgery or concurrently with radiation. RESULTS: The actuarial freedom from biochemical failure for the entire group at 4 years was 67% ± 5.3%. An identical 67% control rate was seen at 5 years for the first 50 enrolled patients, whose median follow-up was longer at 43 months. One acute grade 3 genitourinary toxicity occurred, with no acute grade 3 gastrointestinal and no late grade 3 toxicities observed. On univariate analysis, higher Gleason score (P = .006), PSA doubling time ≤12 months (P = .03), perineural invasion (P = .06), and negative margins (P = .06) showed association with unsuccessful salvage. On multivariate analysis, higher Gleason score (P = .057) and negative margins (P = .088) retained an association with biochemical failure. CONCLUSIONS: Hypofractionated radiotherapy (65 Gy in 2.5 Gy fractions in about 5 weeks) reduces the length of treatment by from 1-½ to 3 weeks relative to other treatment schedules commonly used, produces low rates of toxicity, and demonstrates encouraging efficacy at 4 to 5 years. Hypofractionation may provide a convenient, resource-efficient, and well-tolerated salvage approach for the estimated 20,000 to 35,000 US men per year experiencing biochemical recurrence after prostatectomy.

Skill based mentored laparoscopy course participation leads to laparoscopic practice expansion and assists in transition to robotic surgery.

PURPOSE: Prior studies suggest poor long-term incorporation of laparoscopy into urology practice after a postgraduate course. We evaluated the influence of the American Urological Association Mentored Laparoscopy Course on urologist clinical practice. MATERIALS AND METHODS: The 2-day Mentored Laparoscopy Course includes lectures, standardized dry laboratory training with videotape analysis and a porcine laboratory with consistent mentors. Surveys to assess the impact of the course were sent in April 2010 to the 153 urologists who had taken the course from 2004 through 2009. RESULTS: Of the 153 surveys 91 (60%) were returned a mean of 34.5 months after completing the course. Of the respondents 82% were in a group private practice, followed by solo private practice (15%) and full-time academic practice (3%). Of the respondents 92% reported that they had sutured laparoscopically, 52% had sutured a bleeding vessel and 51% had performed reconstructive laparoscopy since taking the course. Of the respondents 77% reported that their laparoscopic practice had expanded since taking the course (mean 2.9 cases monthly). Of the 41 respondents (45%) who now performed robotic surgery (mean 3.8 cases monthly) 39 (95%) thought that the course experience had helped with the transition into robotic surgery. Overall survey respondents were pleased with the experience during the course with 89 of 91 (98%) stating that they would recommend the course to a colleague. CONCLUSIONS: Long-term results reveal that the American Urological Association Mentored Laparoscopy Course attendees reported expansion in their laparoscopic practice since taking the course. They described the course as benefiting the transition to robotic surgery.

Hand-assisted laparoscopy confers equal efficacy in simple and radical nephrectomy.

BACKGROUND AND OBJECTIVES: To evaluate outcomes for simple hand-assisted laparoscopic nephrectomy (HALSN). METHODS: A retrospective chart review was performed at our institution for all patients who had undergone HALSN from January 2002 to January 2009. Thirty-three patients underwent HALSN during this time period and were matched with 33 patients who underwent radical handassisted laparoscopic nephrectomy (HALRN). RESULTS: Operative times were similar between both groups (301 vs 286 min for HALSN vs HALRN; P=.54). There were no intraoperative or postoperative transfusions in either group. There was one conversion to open nephrectomy in the HALSN group in a patient with xanthogranulomatous pyelonephritis and no conversions in the HALRN group. The mean opioid equivalence requirement was not statistically different between both groups (110 vs 120 for HALSN vs HALRN, P=.70). Mean hospital stay was similar for patients undergoing HALSN and HALRN (5.0±3.8 days vs 4.0±1.2 days, P=.63). There was 1 major complication in the HALSN group (pulmonary embolus) and no major complications in the HALRN group. Rates of minor complications were comparable between the 2 groups (18% vs 24% for HALSN vs HALRN). CONCLUSIONS: HALSN may be associated with similar operative times and length of postoperative hospital stay as well as comparable complication rates compared to HALRN.

Flexible Ureteroscopy as the New Standard for the Management of Renal Transplant Urolithiasis <15 mm: A Single-Center Experience.

Objectives: To determine the safety and efficacy of flexible ureteroscopy in the treatment of transplant urolithiasis. Materials and Methods: We reviewed a single-center series of 2652 patients who underwent surgical treatment for nephrolithiasis at our institution from 2009 to the present day to identify all patients undergoing ureteroscopy for treatment of transplant lithiasis. Results: We identified 18 patients who underwent ureteroscopy for treatment of urolithiasis within the transplanted kidney or ureter. The majority of the procedures were performed using a retrograde approach with flexible ureteroscopy, with one patient undergoing antegrade ureteroscopy and two patients requiring semirigid ureteroscopy. Holmium:yttrium-aluminum-garnet laser lithotripsy was utilized in all but one case, which was performed using basket extraction. There were no intraoperative complications reported. Four patients had small stone fragments on postoperative imaging, three of which were observed. One patient required repeat ureteroscopy for persistent distal ureteral stone. Conclusion: Retrograde ureteroscopy is a feasible, safe, and effective intervention for the treatment of transplant lithiasis. Minimal intraoperative or postoperative complications were reported, and only one patient required additional intervention for residual stone burden.

Microwave Ablation of Renal Cell Carcinoma.

Management options for small renal masses include active surveillance, partial nephrectomy, radical nephrectomy, and thermal ablation. For tumors typically ≤3 cm in size, thermal ablation is a good option for those desiring an alternative to surgery or active surveillance, especially in patients who are considered high surgical risk. We favor microwave ablation because of the more rapid heating, higher temperatures that overcome the heat sink effect of vessels, reproducible cell kill, and a highly visible ablation zone formed by water vapor that corresponds well to the zone of necrosis. For central tumors, we favor cryoablation because of the slower formation of the ablation zone and less likelihood of damage to the collecting system. With microwaves, it is important to monitor the ablation zone in real time (ultrasound is the best modality for this purpose), avoid direct punctures of the collecting system, and to place probes tangential to the collecting system to avoid burning open a persistent tract between the urothelium and extrarenal spaces or causing strictures. The surgical steps described in this video cover our use of high-frequency jet ventilation with general anesthesia to minimize organ motion, initial imaging and targeting, probe insertion, hydrodissection (a technique that enables displacement of adjacent structures), the ablation itself, and finally our dressing. Postoperative cares typically consist of observation with a same-day discharge or an overnight stay. Follow-up includes a magnetic resonance imaging abdomen with and without contrast, chest X-ray, and laboratories (basic metabolic panel, complete blood count, and C-reactive protein) 6 months postablation. Overall, percutaneous microwave ablation is an effective and safe treatment option for renal cell carcinoma in both T1a and T1b tumors in selected patients with multiple studies showing excellent oncologic outcomes when compared with partial and radical nephrectomy.

Influence of Lower Pole Infundibulopelvic Angle on Success of Retrograde Flexible Ureteroscopy and Laser Lithotripsy for the Treatment of Renal Stones.

Objectives: Influence of renal anatomy on success rates for shockwave lithotripsy has been reported in the literature with emphasis on lower pole anatomy. Influence of renal anatomy has not been evaluated in the setting of ureteroscopy and laser lithotripsy for stone treatment. This study analyzed the influence of infundibulopelvic angle (IPA) of the lower pole on the outcomes of ureteroscopy and laser lithotripsy with respect to stone-free rate and surgical recurrence. Materials and Methods: We retrospectively analyzed 735 renal units undergoing retrograde flexible ureteroscopy (fURS) with laser lithotripsy between January 2009 and December 2016. All cases were performed at a single institution. No exclusion criterion was applied with regard to preoperative stone location. Success was defined as no evidence of residual stone fragments on kidney, ureter, and bladder radiograph within 2 months of surgery. Failure was defined as any stone present on imaging. Lower pole IPA was measured on intraoperative retrograde pyelogram as described by Elbahanasy et al. Univariate and multivariate analyses of factors contributing to stone-free rate were performed. Secondary outcomes included surgical recurrence-free survival. Results: Of the 735 cases evaluated, 243 cases had a retrograde pyelogram stored in our Picture Archiving and Communication System (PACS) sufficient for IPA interpretation. Of these patients, 122 (50%) were women. In total, 127 patients (52.3%) were stone free on follow-up imaging, whereas 116 (47.7%) had residual stone burden. In total, 144 (59%) patients had ≤3 mm stone burden on follow-up imaging. In multivariate analysis, residual stone fragments were significantly associated with acute IPA <90° (<0.001), lower pole stones preoperatively (<0.001), and larger stone size (0.001). IPA <90° and larger stone size were both found to be statistically significantly associated with need for repeat surgery. Conclusions: Our data show that more acute IPA and larger preoperative stone size negatively affect stone-free rate and need for repeat surgery after retrograde fURS with laser lithotripsy for treatment of renal stones.

Lower Socioeconomic Status is Associated With Adverse Urinary Markers and Surgical Complexity in Kidney Stone Patients.

OBJECTIVE: To determine if socioeconomic status (SES) correlates with severity of kidney stone disease and 24-hour urine parameters. MATERIALS AND METHODS: An IRB approved prospectively maintained database for nephrolithiasis was retrospectively analyzed for both 24-hour urine results and surgical procedures performed from 2009 to 2019. Severely distressed communities (SDC) were categorized as those with a Distressed Communities Index (DCI), a composite measure of SES, score in the top quartile (lowest for SES). Univariate and multivariate analyses were performed to evaluate the strength of the association of DCI on: stone size at presentation, need for and type of surgical procedure, need for staged surgery and specific stone risk factors in 24-hour urine collections. RESULTS: Surgical procedures were performed on 3939 patients (1978 women) who were not from SDC and 200 (97 women) from SDC. Patients from SDC were older (57.1 years vs 54.2 years; P = .009). Patients from SDC were more likely to undergo proportionally more invasive procedures (17.5% vs 11.6%; P = .011) and require staged surgery at a higher rate (13.0% vs 8.5%; P = .028). Men from SDC had larger stones (12.5 mm vs 9.7 mm; P = .001). Among 24-hour urine results from 2454 patients (1187 women), DCI was not correlated with sodium, calcium, magnesium, volume, oxalate, phosphate, and pH levels. Higher DCI (lower SES) correlated with lower urine citrate (P = .001) and lower urine potassium (P = .002). CONCLUSION: SES correlates with larger stone burden at the time of urologic intervention, requires proportionally more invasive procedures and more staged procedures. Lower SES correlated with lower urine citrate and potassium.

Comparing Outcomes for Patients with Clinical T1b Renal Cell Carcinoma Treated With Either Percutaneous Microwave Ablation or Surgery.

OBJECTIVE: To compare perioperative and oncologic outcomes for patients with clinical T1b renal cell carcinoma following treatment with microwave ablation (MW), partial nephrectomy (PN), or radical nephrectomy (RN). METHODS: Comprehensive clinical and pathologic data were collected for nonmetastatic renal cell carcinoma patients with cT1b tumors following MW, PN, or RN from 2000 to 2018. Local recurrence-free, metastasis-free, cancer-specific and overall survival were estimated using Kaplan-Meier method. Prognostic factors for complications and survival were determined using logistic regression and Cox hazard models, respectively. RESULTS: A total of 325 patients (40 MW, 74 PN, and 211 RN) were identified. Patients treated with MW were older with higher Charlson comorbidity indices compared to surgical patients. Median length of hospitalization was shorter for MW compared to surgical patients (1 day vs 4 days, P <.0001). Post-treatment estimated glomerular filtration rate decreased by median 4.5% for MW compared to 3.2% for PN (P = .58) and 29% for RN (P <.001). Median follow-up was 34, 35, and 49 months following MW, PN, and RN, respectively. Estimated 5-year local recurrence-free survival was 94.5% for MW vs 97.9% for PN (P = .34) and 99.2% for RN (P = .02). Two patients recurred after MW and underwent repeat ablation without subsequent recurrence. No difference in 5-year metastasis-free survival or cancer-specific survival was found among MW, PN, or RN. Four (10%) MW patients had high-grade complication. Only prior abdominal surgery predicted high-grade complication (OR 6.29, P = .017). CONCLUSION: Microwave ablation is a feasible alternative to surgery in select comorbid patients with clinical T1b renal cell carcinoma.

Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin.

OBJECTIVE: To evaluate the recurrence-free survival (RFS) rate of patients taking cardioprotective aspirin after intravesical bacille Calmette-Guérin (BCG) for high-grade noninvasive urothelial carcinoma of the bladder, as preventing the recurrence of superficial bladder cancer might decrease patient morbidity and mortality from this disease, and nonsteroidal anti-inflammatory agents (NSAIDs) have shown promise in preclinical prevention through inhibition of the prostaglandin pathway and other mechanisms. PATIENTS AND METHODS: In all, 43 patients with carcinoma in situ (CIS) and/or high-grade papillary bladder cancer were treated with intravesical BCG. Patients were stratified according to whether they took cardioprotective aspirin after treatment, and Kaplan-Meier curves of RFS were compared by log-rank analysis. Multivariable analysis was used for potentially confounding factors, including maintenance BCG, the presence of CIS, and smoking status. RESULTS: Of patients taking cardioprotective aspirin, the 5-year RFS rate was 64.3%, compared with 26.9% for patients not taking aspirin, with a significantly higher RFS by univariable log rank analysis (P = 0.03). Even after adjusting for the other factors by multivariable analysis, aspirin seems to affect recurrence (hazard ratio 0.179, P = 0.001). Maintenance BCG (hazard ratio 0.233, P = 0.02) and smoking history (hazard ratio 3.199, P = 0.05) also significantly affected recurrence. CONCLUSION: There was a significantly higher RFS rate in patients taking cardioprotective aspirin after intravesical BCG therapy for bladder cancer. The results of this study support the further investigation of aspirin and other NSAIDs as preventive agents in patients being treated for superficial bladder cancer.

Flexible and rigid cystoscopy in women.

PURPOSE: Previous studies have evaluated the tolerability of rigid versus flexible cystoscopy in men. Similar studies, however, have not been performed in women. We sought to determine whether office-based flexible cystoscopy was better tolerated than rigid cystoscopy in women. MATERIALS AND METHODS: Following full IRB approval, women were prospectively randomized in a single-blind manner. Patients were randomized to flexible or rigid cystoscopy and draped in the lithotomy position to maintain blinding of the study. Questionnaires evaluated discomfort before, during, and after cystoscopy. RESULTS: Thirty-six women were randomized to flexible (18) or rigid (18) cystoscopy. Indications were surveillance (16), hematuria (15), recurrent UTIs (2), voiding dysfunction (1), and other (2). All questionnaires were returned by 31/36 women. Using a 10-point visual analog scale (VAS), median discomfort during the procedure for flexible and rigid cystoscopy were 1.4 and 1.8, respectively, in patients perceiving pain. Median recalled pain 1 week later was similar at 0.8 and 1.15, respectively. None of these differences were statistically significant. CONCLUSIONS: Flexible and rigid cystoscopy are well tolerated in women. Discomfort during and after the procedure is minimal in both groups. Urologists should perform either procedure in women based on their preference and skill level.

Management of Indiana pouch stones through a percutaneous approach: A single center experience.

OBJECTIVE: We present our experience of the treatment of reservoir stones using a percutaneous approach in patients with Indiana pouch urinary diversions. MATERIAL AND METHODS: Patients who were treated percutaneously for Indiana pouch reservoir stones between January 2008 and December 2018 were identified from the hospital database, and their data were retrospectively analyzed. Patient charts were reviewed for stone burden, surgery details, and postoperative complications. The Indiana pouch was punctured under a direct ultrasound guidance, and a 30F sheath was placed into the pouch. A urologist removed the stones by inserting a rigid nephroscope through the sheath. A Foley catheter was left in the pouch through the percutaneous tract and opened to drainage. RESULTS: Seven patients (mean age: 47.3±14.7 years) were included. All patients were stone free after the procedure. The median stone number was 3 (range: 1-8). The mean maximum stone diameter was 24.4±4.9 mm (range: 19-33 mm). Six patients were successfully treated in one session, whereas 1 patient required two treatment sessions. The median postoperative hospital admission was 1 day (range: 1-5 days). The Foley catheters were removed after a median of 18 days (range: 10-19 days). No major complications were reported. CONCLUSION: The percutaneous approach for Indiana pouch reservoir stones treatment ensures direct and safe management without major periprocedural complications.

External Validation of the Recurrence of Kidney Stone Nomogram in a Surgical Cohort.

Objective: To assess the performance of recurrence of kidney stone (ROKS) nomogram in identifying first-time stone formers who will require future stone procedures. Materials and Methods: From January 2009 to February 2016, 2287 patients underwent surgical treatment for nephrolithiasis at our institution and 498 of them were eligible for this study. We defined recurrence as repeat surgery for symptomatic nephrolithiasis. We analyzed the performance of the nomogram with respect to discrimination, calibration, and the clinical net benefit. We also examined the performance of each individual variable from the nomogram. Results: Over a median follow-up of 4.8 years (mean 4.6, IQR 3.1-6.1), 88 patients (17.7%) had recurrent nephrolithiasis requiring surgical treatment. The ROKS nomogram demonstrated moderate discriminative ability (AUC 0.655 for 2 years and 0.605 for 5 years). Calibration of the ROKS nomogram-based predictions was poor and net clinical benefit was minimal. Three of 11 predictors from the nomogram were statistically significantly associated with the risk of repeat surgery, with two of them representing similar clinical scenarios, namely symptomatic and nonsymptomatic renal stones. Conclusion: ROKS nomogram demonstrated limited discrimination and calibration in predicting the risk of repeat surgery for symptomatic nephrolithiasis in our cohort of first-time stone formers. This may be caused by the differences between stone patients who do and do not require surgery and suggests the need for development of more precise prediction instruments.

Development of a Risk-stratified Approach for Follow-up Imaging After Percutaneous Thermal Ablation of Sporadic Stage One Renal Cell Carcinoma.

OBJECTIVE: To analyze risk factors and patterns of RCC recurrence following percutaneous ablation for stage 1 tumors and develop risk-stratified follow-up imaging protocols. METHOD: Biopsy-proven sporadic stage 1 RCC patients treated with percutaneous microwave ablation (MWA) or cryoablation (CA) from 2002 to 2017 were included. Kaplan-Meier analysis was used to estimate local and distant recurrence-free survival, cancer-specific survival and metastatic-free survival. Multivariable models were used to identify risk factors associated with recurrence. RESULTS: A total of 256 patients with stage 1 RCC (215 T1a, 41 T1b) were treated with percutaneous MWA (178 subjects) or CA (78 subjects). Recurrence was identified in 23 patients (16 local, 7 distant). Clinical T stage (HR 2.46, 95% CI 1.06-5.72, P = .04) and tumor grade (HR 4.17, 95% CI 1.17-14.76, P = .03) were independent predictors of recurrence. Recurrence was not associated with Nephrometry score, cystic tumors, ablation modality (CA vs MWA) or gender. Five-year cancer-specific survival, and metastatic-free survival were 98.6% and 97.4%, respectively. Patients were stratified into 2 groups: reduced risk stage 1 (no risk factors) or elevated risk stage 1 (≥1 risk factor). Recurrence risk was higher in the elevated-risk group (HR = 3.19, 95% CI 1.35-7.53, P = .008). Five-year overall recurrence-free survival (local + distant) was higher in reduced-risk vs elevated-risk cohorts, 88% vs 69%, P = .005. CONCLUSION: High nuclear grade or T1b tumors have increased recurrence risk following percutaneous thermal ablation for stage 1 RCC. Current postablation follow-up protocols may be modified for individual recurrence risk to allow more frequent imaging for elevated-risk patients, while enabling less frequent imaging for reduced-risk patients.

Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.

PURPOSE: To evaluate whether hypofractionation is well tolerated and to preliminarily assess biochemical control of this regimen in a postprostatectomy, salvage setting. METHODS AND MATERIALS: A retrospective analysis was performed in 50 patients treated between May 2003 and December 2005 with hypofractionated radiotherapy for biochemical recurrence after radical prostatectomy. Radiotherapy was prescribed to the prostatic fossa to 65-70 Gy in 26-28 fractions of 2.5 Gy each, using intensity-modulated radiotherapy with daily image localization. Toxicities were scored using a modified Radiation Therapy Oncology Group scale and the Fox Chase modification of Late Effects Normal Tissue scale. The median follow-up was 18.9 months (range, 5.3-35.9). RESULTS: No Grade 3 or greater acute or late toxicities were observed. Grade 2 toxicities included four acute genitourinary, one acute gastrointestinal, two late genitourinary, and two late gastrointestinal toxicities. Of the 50 patients, 39 demonstrated a continuous biochemical response after salvage therapy, 3 had an initial response before prostate-specific antigen failure, and 7 had prostate-specific antigen progression, 1 of whom died of progressive metastatic disease. Finally, 1 patient discontinued therapy because of the diagnosis of a metachronous pancreatic cancer and died without additional prostate cancer follow-up. All remaining patients were alive at the last follow-up visit. A lower presalvage prostate-specific antigen level was the only significant prognostic factor for improved biochemical control. The estimated actuarial biochemical control rate at 2 years was 72.9%. CONCLUSIONS: The toxicity and early biochemical response rates were consistent with expectations from conventional fractionation. Additional follow-up is required to better document the biochemical control, but these results suggest that hypofractionation is a well-tolerated approach for salvage radiotherapy.

Oncological outcomes of hand-assisted laparoscopic radical nephrectomy for clinically localized renal cell carcinoma: a single-institution study with >or=3 years of follow-up.

OBJECTIVE: To evaluate the intermediate-term outcomes of hand-assisted laparoscopic radical nephrectomy (HALRN) for clinically organ-confined renal cell carcinoma (RCC). PATIENTS AND METHODS: We retrospectively reviewed patients who had HALRN for clinically organ-confined RCC at the University of Wisconsin from 1996 to 2003. All patients with pathologically confirmed RCC and with >or=3 years of follow-up were included in a retrospective chart review of variables before, during and after HALRN, as well as the clinical outcomes. RESULTS: In all, 75 patients had HALRN in the study period; their mean age was 59 years, body mass index 29 kg/m(2), operative duration 227 min, estimated blood loss 130 mL, and none required conversion to open nephrectomy. The median time to first oral intake was 2.5 days and the median hospital stay 4 days. On pathological examination the mean tumour size was 5.8 cm; 70% were pT1, 26% pT2 and 4% pT3; 82% were clear cell, 9% papillary, 8% chromophobe and 1% collecting duct carcinoma. Of the 65 patients who had a follow-up of >or=36 months (mean 46, range 36-117), the 3- and 5-year disease-free survival rate was 93.4% and 90.2%, respectively; the 3- and 5-year cancer-specific survival rate was 96.5% and 94.4%, respectively. CONCLUSION: Our study suggests that HALRN is a safe and minimally invasive treatment for managing clinically organ-confined RCC, with good intermediate-term oncological outcomes.

Comparison of percutaneous and laparoscopic cryoablation for the treatment of solid renal masses.

OBJECTIVE: The goal of this study was to compare the outcome, complications, and charges of percutaneous renal cryoablation and laparoscopic cryoablation of solid renal masses. MATERIALS AND METHODS: A total of 30 percutaneous renal cryoablations (mean tumor size, 2.1 cm) in 30 patients (mean age, 67.0 years) and 60 laparoscopic renal cryoablations (mean tumor size, 2.5 cm) in 46 patients (mean age, 67.4 years) were compared. The size of the tumor, procedural complications, hospital charges, length of hospital stay, and tumor follow-up parameters were recorded. Monitoring after ablation was performed every 3 months using contrast-enhanced MRI or CT. RESULTS: Both percutaneous cryoablation and laparoscopic cryoablation of solid renal masses had a high technical success rate (30/30 [100%] and 59/60 [98.3%]). There was no significant difference in the rate of residual disease (3/30 [10%] and 4/60 [6.7%], p = 0.68), and the secondary effectiveness rate is 100% for both groups to date. One renal mass treated using laparoscopic cryoablation had a local recurrence, but none of the masses treated using percutaneous cryoablation had a recurrence. The disease-specific survival is 100% in both groups with no significant difference in the mean follow-up time (14.5 vs 14.6 months, p = 1.0) or major complication rate (0/30 [0%] vs 3/60 [5.0%], p = 0.55). For the treatment of solid renal masses, percutaneous cryoablation was associated with 40% lower hospital charges (mean, $14,175 vs $23,618, p < 0.00001) and a shorter hospital stay (mean +/- SD, 1.1 +/- 0.3 vs 2.4 +/- 2.1 days; p < 0.0001) than laparoscopic cryoablation. CONCLUSION: Although certain tumors require laparoscopic intervention because of the location or size of the tumor, percutaneous renal cryoablation is safe and effective and is associated with lower charges when used for the treatment of small renal tumors.